Showing posts with label conflicts of interest. Show all posts
Showing posts with label conflicts of interest. Show all posts

Tuesday, January 25, 2011

The Sell Out of Academia

Pfizer (the biggest drug dealer in the world) buys up academia—again (to make drugs and money off the public’s dime) Part 2:

 Pfizer infiltrates into universities using publically funded academic facilities and resources to make their drugs.  The drugs are sold at huge profits that gouge the public.  We pay no matter what.

An earlier blog pointed to the West Coast takeover of academia.  Now Pfizer buys up academia in New York.  The research hospitals that have sold out include:  Rockefeller University, New York University Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College.

Good bye academic freedom.

I am a dissatisfied taxpayer.  Let'stop public funding these universities that make these contracts with Pfizer using our taxpayer funded resources.  Stop giving donations to these universities.  Fund your local hospitals instead.

http://www.thegovmonitor.com/world_news/united_states/new-york-hospitals-join-pfizer-global-centers-for-therapeutic-innovation-45340.html

Wednesday, January 12, 2011

The Biomedical Industrial Complex: Pfizer Networks with Law Firms and Gives Report Cards

From the AM Law Daily:

"...Over the last year, Pfizer's legal team has developed a ranking system for matters handled by outside firms. They are graded on performance issues ranging from substantive knowledge to responsiveness to willingness to collaborate. Twice a year, Pfizer gives each firm a report card--and then grades them on how well they take the feedback. "We learned a lot about firms," she says, "by whether they welcomed the feedback or responded by saying, 'You got it wrong.'" Pfizer has sought other ways to make the links tighter. Each firm has an in-house relationship partner. Pfizer encourages secondments and has recruited with two firms at law schools, looking for associates who will split their time between the firm and the company." 

For entire article see link:
http://amlawdaily.typepad.com/amlawdaily/2011/01/pfizeroneyearlater.html

Friday, October 22, 2010

Search for doctors with conflicts of interest

A "Docs on Pharma Payroll" Database has been initiated by ProPublica.  It includes a 2009 list of all doctors who have received monetary benefits from Eli Lily, GlaxoSmithKline, AstraZeneca, Pfizer, Merck, J&J and Cephalon.  The total contributions to physicians for 2009 from all seven companies equaled oever $240 million.  Wow.

Here is the link to search for a specific doctor and or drug company:  http://projects.propublica.org/docdollars/

Tuesday, September 21, 2010

Big Money...the Pfizer-Government Influence


Pfizer spent $2.3 million lobbying federal government in 2Q on health, economic issues
Associated Press

09/20/10 5:00 AM PDT

NEW YORK — Pfizer Inc., the world's biggest drugmaker, spent $2.3 million lobbying Congress and federal agencies in the second quarter on health care reform and other health economic issues, according to a recent filing.

The maker of cholesterol blockbuster Lipitor, impotence pill Viagra and children's vaccine Prevnar reduced its spending on lobbying in the second quarter by 60 percent compared with a year ago when its lobbying cost $5.6 million. It is also down 48 percent from the $4.3 million in the first quarter of this year.

New York's Pfizer lobbied on multiple trade agreement issues, including China, South Korea, and Mexico. It also lobbied on health care reform issues, including the use of research comparing the effectiveness of medications and other types of treatment, health information technology, and veterans health issues.

During the April to June period, the company also lobbied on patent reform and prices and rebates for drugs bought through government programs such as Medicare and Medicaid.

Besides Congress, Pfizer lobbied the White House, the Food and Drug Administration, the Centers for Medicare and Medicaid Services, the U.S. Patent and Trademark Office and the departments of Commerce, State, Veterans Affairs and Health and Human Services, according to the July 20 filing with the House clerk's office.

http://www.sfexaminer.com/economy/pfizer-spent-23-million-lobbying-federal-government-in-2q-on-health-economic-issues-103272184.html

Friday, September 17, 2010

What Happens When Biotech Buys a University?

The Sad Saga of Ignacio Chapela


academic freedom in chains
by John Ross
Feb 18, 2004
 
How to destroy Mexican corn, reap maximum profits, and buy a university in one easy lesson...


Seated on the balcony of his appropriately professorial office upon a sun-stroked hillock in the midst of the Life Science complex on the hallowed Berkeley campus of the University of California, the controversial Mexican-born microbiologist Ignacio Chapela, an academic who has dared to lock horns with the potentates of Big Biotech, reflected upon the tenuous status of his employment. "They will never forgive me here," the curly-haired, Cupid-mouthed Chapela sighed disconsolately, his gaze fixed upon the Campanile, the Berkeley campus's most recognizable landmark, as if it were a stand-in for Chancellor Robert Berdahl himself.

For story go to this link:  http://theava.com/04/0218-chapela.html

Monday, September 13, 2010

Bought And Paid For_the Selling of the Academic Community


The Secret Lives of Big Pharma's 'Thought Leaders
September 12, 2010
By Carl Elliott

'In the early 1970s, a group of medical researchers decided to study an unusual question. How would a medical audience respond to a lecture that was completely devoid of content, yet delivered with authority by a convincing phony? To find out, the authors hired a distinguished-looking actor and gave him the name Dr. Myron L. Fox. They fabricated an impressive CV for Dr. Fox and billed him as an expert in mathematics and human behavior. Finally, they provided him with a fake lecture composed largely of impressive-sounding gibberish, and had him deliver the lecture wearing a white coat to three medical audiences under the title "Mathematical Game Theory as Applied to Physician Education." At the end of the lecture, the audience members filled out a questionnaire.

The responses were overwhelmingly positive. The audience members described Dr. Fox as "extremely articulate" and "captivating." One said he delivered "a very dramatic presentation." After one lecture, 90 percent of the audience members said they had found the lecture by Dr. Fox "stimulating." Over all, almost every member of every audience loved Dr. Fox's lecture, despite the fact that, as the authors write, it was delivered by an actor "programmed to teach charismatically and nonsubstantively on a topic about which he knew nothing."

It is tempting to imagine that the Dr. Fox study reveals a deep flaw in the structure of medicine—for example, that health-care workers are too trusting of authority, or that Continuing Medical Education (CME) lectures are a sham. But what the study actually reveals may be something closer to the opposite. If medicine were simple and transparent, pretending to be a medical expert would be very difficult. An audience could spot incompetence right away. Pretending to be a medical expert is possible precisely because medical knowledge is so specialized and opaque. These days an ordinary doctor can no more expect to understand the intricacies of specialized medical research than the driveway mechanic who tinkered with his Volkswagen in 1962 can expect to fully understand the complex, computerized automobiles on the road today. Those who have tried to sit through a medical lecture in a field other than their own will secretly admit that they could have been fooled by Dr. Fox as well.

Since the 1950s, marketers have been taken with the idea that when it comes to spreading the word about unfamiliar products or ideas, some people are far more important than others. The phrase "opinion leader" was made familiar by the sociologists Paul Lazarsfeld and Elihu Katz in their 1955 book, Personal Influence, where they used the term to explain the way that media messages were filtered and spread by personal, face-to-face contact with influential people. It is not hard to see why marketers liked this idea. Mass-media advertising can be expensive. What if there were a way to avoid the masses and simply concentrate on the special people? Today the pharmaceutical industry uses the terms "thought leader" or "key opinion leader"—KOL for short—to refer to influential physicians, often academic researchers, who are especially effective at transmitting messages to their peers. Pharmaceutical companies hire KOL's to consult for them, to give lectures, to conduct clinical trials, and occasionally to make presentations on their behalf at regulatory meetings or hearings.

The KOL is a combination of celebrity spokesperson, neighborhood gossip, and the popular kid in high school. KOL's do not exactly endorse drugs, at least not in ways that are too obvious, but their opinions can be used to market them—sometimes by word of mouth, but more often by quasi-academic activities, such as grand-rounds lectures, sponsored symposia, or articles in medical journals (which may be ghostwritten by hired medical writers). While pharmaceutical companies seek out high-status KOL's with impressive academic appointments, status is only one determinant of a KOL's influence. Just as important is the fact that a KOL is, at least in theory, independent. Medical audiences trusted Dr. Fox partly because he played the part of an expert so convincingly: white coat, gray hair, and a complicated lecture, delivered with authority. But they also trusted him because they had no reason not to trust him. Dr. Fox was not selling a product or pitching an idea. The very implausibility of his charade is part of what made it so persuasive. Dr. Fox appeared to be impartial.

It is not hard to see why pharmaceutical companies would like to have a Dr. Fox speaking on their behalf. Most marketers would like to have a convincing, influential, and apparently independent expert who will deliver the text that they give him. The more interesting question is: Why do so many academic physicians want to be Dr. Fox?

"It strokes your narcissism," says Erick Turner, a psychiatrist at the Oregon Health and Science University. There is the money, of course, which is no small matter. Some high-level KOL's make more money consulting for the pharmaceutical industry than they get from their academic institutions. But the real appeal of being a KOL is that of being acknowledged as important. That feeling of importance comes not so much from the pharmaceutical companies themselves, but from associating with other academic luminaries that the companies have recruited. Academic physicians talk about the experience of being a KOL the way others might talk about being admitted to a selective fraternity or an exclusive New York dance club. No longer are you standing outside the rope trying to catch the doorman's eye, waiting hungrily to be admitted. You are one of the chosen. "You get to hobnob with these mega-thought leaders and these aspiring thought leaders," Turner says. "They make you feel like you're special."

For the rest of the article go to this link:  http://chronicle.com/article/article-content/124335/

Monday, July 12, 2010

Pfizer Continued Unethical Business Practices, Continue to Make the Bucks

Martha Rosenberg writes an article which provides a summary of how Pfizer is banking the bucks with their continued unethical business practices, with their involvement in questionable practices with government agencies and how it causes serious health harm to the public consumer.

An interesting point in the article is made when it hypothesizes that the government can't get tough on Pfizer by preventing Pfizer to sell drugs to Medicare, Medicaid and VA. "The government is not really in a position to be cutting itself off from all that medicine."

Why not? Why can't unethical companies loose patent rights when they use unethical business practices? Why not let a different, but ethical company make the same drugs and sell them to Medicare, Medicaid and the VA?

Although the article is good, Rosenberg forgets to mention, however, that after Pfizer was fined 2.3 Billion dollars for unethical business practices by the US government, Pfizer CEO Jeffry Kindler was appointed to the Federal Reserve Bank of New York. The Federal Reserve is one of the single most influential bodies for setting US monetary standards and policy in the United States. Hello...anyone home?

Rosenberg's article is below:

Pfizer: The Drug Giant That Makes Bank from Drugs That Can Kill You
By Martha Rosenberg, AlterNet Posted on July 10, 2010, http://www.alternet.org/story/147467/

Pfizer: The Drug Giant That Makes Bank from Drugs That Can Kill You
By Martha Rosenberg, AlterNetPosted on July 10, 2010, Printed on July 12, 2010http://www.alternet.org/story/147467/
The drug company Pfizer is best known for Lipitor, a drug that brings cholesterol down and Viagra, a drug that brings other things up.

But the "world's largest research-based pharmaceutical company" which sits between Goldman Sachs and Marathon Oil on the Fortune 500, is also closely associated with a seemingly never-ending series of scandals.

To say Pfizer's been accused of wrongdoing is like saying BP had an oil spill. Other drug companies have a portfolio of products, Pfizer has a portfolio of scandals including, but not limited to, Chantix, Lipitor, Viagra, Geodon, Trovan, Bextra, Celebrex, Lyrica, Zoloft, Halcion and drugs for osteoarthritis, Parkinson's disease, kidney transplants and leukemia.
For more go to this LINK: http://www.alternet.org/story/147467/

Thursday, January 21, 2010

PHARMA NOT WANTED AT MEDICAL SCHOOLS

Pfizer Worker Photographed Protesters at Harvard
Published in NEW YORK TIMES, MARCH 3, 2009
By DUFF WILSON
Harvard Medical School’s rules say that students on campus are supposed to be off-limits to drug company representatives.
That is why David Tian, a first-year Harvard medical student, said he found it “strange and off-putting” last fall when a man who identified himself as a Pfizer employee took a cellphone photo of students as they demonstrated against pharmaceutical industry influence on campus. “We could only assume he intended to share this with his company,” Mr. Tian said.
The students did not get the man’s name, but they took his picture.
Asked about the mysterious Pfizer man on campus and shown his picture, a company spokesman said he had recently contacted the employee and concluded that he had done nothing wrong. Declining to name him, the spokesman, Ray Kerins, said the employee had photographed the students for personal use.
Mr. Kerins preferred to talk about Pfizer’s support of the medical school, which, according to Harvard officials, includes private payments to at least 149 faculty members, corporate donations of $350,000 to the school last year, $234,000 for continuing medical education classes, and two Pfizer-financed research projects on campus.
“We’ve got top-class collaboration in place with leading medical institutions around the world, and we’re very proud of them,” Mr. Kerins said.
Whatever the unidentified Pfizer representative was up to, Mr. Tian and other students said they saw him again two weeks after the campus protest, at a public lecture on campus about conflicts of interest in medical research.
Drug industry employees are “all over the place,” the lecturer, Dr. Catherine D. DeAngelis, the editor of the Journal of the American Medical Association, said last week. “It’s a free country,” she said. “I’m not hiding anything. Maybe they’ll even listen to what I say and think about what they’re doing.”

Monday, January 4, 2010

Academic Sell Out

Here is a link to a good book review written by Sheldon Krimsky regarding Jennifer Washburn's treatise on the corporate corruption of higher education in a book called University Inc.

If the public would realize that their hard earned money, going to universities through mandated taxes, are not being used in the public’s interests, and not being used for public health and safety to protect them and their children, but only to line the pockets of the rich, it just might result in a public outcry.

In this book, University Inc., it may very well spell out some of the major problems outlining how academia has sold their soul and no longer represents the public’s interests.

Sunday, November 1, 2009

Public Trust in Public Health and Safety


Here is a link to a "must read", tongue in cheek article regarding public rights to public health and safety,.... or rather the lack of it. It is worth a read since it holds many truths about how our legal and regulatory systems are designed to enhanced unfettered corporate interests, crippling the public's trust and rights to public health and safety. Written by Carolyn Raffensperger...it is a winner.

Friday, October 2, 2009

California Dina Padilla Runs for Insurance Commissioner, Claiming Fraud Is Used Against Injured Workers

Dina Padilla is an advocate for injured workers to obtain medical care. Dina is running for insurance commissioner to combat against the fraud which pointingly deny worker's their right to healthcare. She is a voice for the people and a voice for justice. Watch her video here!

Friday, August 28, 2009

Corrupt Doctors: The Untold MOLD Story


Sharon Kramer, an expert on mold and ACOEM spoke at a press conference called by the California Coalition For Workers Memorial Day for injured workers at the Downey toxic dump site. She spoke on the conflict of interest between the trade group ACOEM and the need to defend people who are sickened by mold. She also reported on her efforts to get a Congressional investigation on this conflict of interest by ACOEM and the role of Senator Edward Kennedy on deleting this aspect in this important expose in a Congressional study. www.workersmemorialday.org
source: http://www.blip.tv/file/2520407

Monday, June 15, 2009

Risks in Embryonic Stem Cell Clincial Trials: Spinal Injury Patients Use Caution


(caption: picture of a teratoma, a type of cancer associated with human embryonic stem cells)

I would highly advise those families who have a loved one facing the difficult and tragic situation of incurring a spinal chord injury, to use caution if asked to enter Geron’s human embryonic stem cell clinical trial. Families and patients should seek both objective and independent scientific and legal counsel before giving signed consent to participate.


Clinical trials are dangerous, especially clinical trials involving new technologies such as human embryonic stem cells. Patients may be taking on more than they bargained for since research institutions often hide the dangers associated with human embryonic stem cell research, leaving the public ignorant of the real risks.

Make sure that the independent experts you choose to counsel with have no conflicts of interest with Geron, which unfortunately is sometimes hard to determine. Ask them if they, their colleagues or institution are obtaining any monetary incentives regarding promoting the Geron trial. If they are, seek other advice.

Although it may seem difficult under your dire circumstances, do not allow the physicians involved to alarm you into making a decision too quickly. Read the informed consent document thoroughly. Let your attorney read it. Make sure you understand every sentence in the informed consent contract.

Do not underestimate the risks noted in the consent form…even if they are written in small print or appear innocuous. You should have a clear appreciation and understanding of the facts and risks involved. You should know that cancer and autoimmune disorders are real risks implicated with this trial.

Keep in mind that this is a SAFETY trial for the use of human embryonic stem cells and not an efficacy trial. It is being performed to determine if this embryonic stem cell treatment will harm humans. The trial has not been designed to cure you.

Geron’s human embryonic stem cell is a dangerous trial, the safety outcome of which is not only measured within the initial months, but also, decades later.

Contact me if you have any further questions at Watchdogonscience@comcast.net

Wednesday, February 13, 2008

Public Health Report-Suppressed

Government Suppresses Major Public Health Report
By Sheila Kaplan

Here’s the report that top officials of the Centers for Disease Control and Prevention thought was too hot for the public to handle—and the story behind it.Download Excerpts from the ReportFor more than seven months, the nation’s top public health agency has blocked the publication of an exhaustive federal study of environmental hazards in the eight Great Lakes states, reportedly because it contains such potentially “alarming information” as evidence of elevated infant mortality and cancer rates.Researchers found low birth weights, elevated rates of infant mortality and premature births, and elevated death rates from breast cancer, colon cancer, and lung cancer.The 400-plus-page study, Public Health Implications of Hazardous Substances in the Twenty-Six U.S. Great Lakes Areas of Concern, was undertaken by a division of the Centers for Disease Control and Prevention at the request of the International Joint Commission, an independent bilateral organization that advises the U.S. and Canadian governments on the use and quality of boundary waters between the two countries. The study was originally scheduled for release in July 2007 by the IJC and the CDC’s Agency for Toxic Substances and Disease Registry (ATSDR).The Center for Public Integrity has obtained the study, which warns that more than nine million people who live in the more than two dozen “areas of concern”—including such major metropolitan areas as Chicago, Cleveland, Detroit, and Milwaukee—may face elevated health risks from being exposed to dioxin, PCBs, pesticides, lead, mercury, or six other hazardous pollutants.In many of the geographic areas studied, researchers found low birth weights, elevated rates of infant mortality and premature births, and elevated death rates from breast cancer, colon cancer, and lung cancer.Since 2004, dozens of experts have reviewed various drafts of the study, including senior scientists at the CDC, Environmental Protection Agency, and other federal agencies, as well as scientists from universities and state governments, according to sources familiar with the history of the project.“It raises very important questions,” Dr. Peter Orris, a professor at the University of Illinois School of Public Health in Chicago and one of three experts who reviewed the study for ATSDR, told the Center. While Orris acknowledged that the study does not determine cause and effect — a point the study itself emphasizes — its release, he said, is crucial to pointing the way for further research. “Communities could demand that those questions be answered in a more systematic way,” he said. “Not to release it is putting your head under the sand.”In a December 2007 letter to ATSDR in which he called for the release of the study, Orris wrote: “This report, which has taken years in production, was subjected to independent expert review by the IJC’s Health Professionals Task Force and other boards, over 20 EPA scientists, state agency scientists from New York and Minnesota, three academics (including myself), and multiple reviews within ATSDR. As such, this is perhaps the most extensively critiqued report, internally and externally, that I have heard of.”Last July, several days before the study was to be released, ATSDR suddenly withdrew it, saying that it needed further review. In a letter to Christopher De Rosa, then the director of the agency’s division of toxicology and environmental medicine, Dr. Howard Frumkin, ATSDR’s chief, wrote that the quality of the study was “well below expectations.” When the Center contacted Frumkin’s office, a spokesman said that he was not available for comment and that the study was “still under review.”De Rosa, who oversaw the study and has pressed for its release, referred the Center’s requests for an interview to ATSDR’s public affairs office, which, over a period of two weeks, has declined to make him available for comment. In an e-mail obtained by the Center, De Rosa wrote to Frumkin that the delay in publishing the study has had “the appearance of censorship of science and distribution of factual information regarding the health status of vulnerable communities.”Some members of Congress seem to agree. In a February 6, 2008, letter to CDC director Dr. Julie Gerberding, who’s also administrator of ATSDR, a trio of powerful congressional Democrats—including Rep. Bart Gordon of Tennessee, chairman of the Committee on Science and Technology—complained about the delay in releasing the report. The Center for Public Integrity obtained a copy of the letter to Gerberding, which notes that the full committee is reviewing “disturbing allegations about interference with the work of government scientists” at ATSDR. “You and Dr. Frumkin were made aware of the Committee’s concerns on this matter last December,” the letter adds, “but we have still not heard any explanation for the decision to cancel the release of the report.”Canadian biologist Michael Gilbertson, a former IJC staffer and another of the three peer reviewers, told the Center that the study has been suppressed because it suggests that vulnerable populations have been harmed by industrial pollutants. “It’s not good because it’s inconvenient,” Gilbertson said. “The whole problem with all this kind of work is wrapped up in that word ‘injury.’ If you have injury, that implies liability. Liability, of course, implies damages, legal processes, and costs of remedial action. The governments, frankly, in both countries are so heavily aligned with, particularly, the chemical industry, that the word amongst the bureaucracies is that they really do not want any evidence of effect or injury to be allowed out there.”The IJC requested the study in 2001. Researchers selected by the ATSDR not only reviewed data from hazardous waste sites, toxic releases, and discharges of pollutants but also, for the first time, mapped the locations of schools, hospitals, and other facilities to assess the proximity of vulnerable populations to the sources of environmental contaminants. In March 2004, an official of the IJC wrote to De Rosa to thank him for his role in the study, saying that he was “enthusiastic about sharing this information with Great Lakes Basin stakeholders and governments,” and adding, “You are to be commended for your extraordinary efforts.”Unlike his Canadian counterpart, however, the ATSDR’s Frumkin seems anything but thankful. De Rosa, a highly respected scientist with a strong international reputation from his 15 years in charge of ATSDR’s division of toxicology and environmental medicine, was demoted after he pushed Frumkin to publish the Great Lakes report and other studies. De Rosa is seeking reinstatement to his former position, claiming that Frumkin illegally retaliated against him. Phone calls to ATSDR seeking comment about the pending personnel dispute were not returned.“I think this is really pretty outrageous, both to Chris personally and to the report,” Dr. David Carpenter, a professor of public health at the State University of New York at Albany and another of ATSDR’s peer reviewers, told the Center for Public Integrity.Some members of Congress have also taken De Rosa’s side. That same February 6 letter to Gerberding, which was co-signed by Rep. Brad Miller of North Carolina, chairman of the Subcommittee on Investigations and Oversight of the Science and Technology Committee, and Rep. Nick Lampson of Texas, chairman of the Subcommittee on Energy and Environment, expressed concern that “management may have retaliated against” De Rosa for blowing the whistle on ATSDR’s conduct related to this investigation and another involving work on formaldehyde in trailers supplied by the Federal Emergency Management Agency to victims of hurricanes Katrina and Rita. “The public is well served by federal employees willing to speak up when federal agencies act improperly, and Congress depends upon whistle blowers for effective oversight,” the letter states. “We will not tolerate retaliation against any whistle blowers.”Barry Johnson, a retired rear admiral in the U.S. Public Health Service and a former assistant administrator of ATSDR, told the Center that before he left in 1999 he recommended that the agency investigate the dangers that chemical contaminants might pose to residents of the Great Lakes states.“This research is quite important to the public health of people who reside in that area,” Johnson said of the study. “It was done with the full knowledge and support of IJC, and many local health departments went through this in various reviews. I don’t understand why this work has not been released; it should be and it must be released. In 37 years of public service, I’ve never run into a situation like this.”Sheila Kaplan is a journalist who divides her time between Washington, D.C., and Northern California. Research support for this story was provided by the Nation Institute Investigative Fund.